Results 131 to 140 of about 2,497,031 (299)
Molecular Oncology, EarlyView.CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Activation of different split functionalities on re-association of RNA–DNA hybrids
, 2013 Kirill A. Afonin +9 more
openalex +2 more sources
Functional genomics of the human epididymis: Further characterization of efferent ducts and model systems by single‐cell RNA sequencing analysis [PDF]
, 2023 Shih‐Hsing Leir +2 more
openalex +1 more source
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
High-performance virtual screening by targeting a high-resolution RNA dynamic ensemble
, 2018 Laura R. Ganser +7 more
openalex +2 more sources
Novel domains in the hnRNP G/RBMX protein with distinct roles in RNA binding and targeting nascent transcripts [PDF]
, 2010 Rasha Kanhoush +5 more
openalex +1 more source
RNA-seq coupling two different methods of castration reveals new insights into androgen deficiency-caused degeneration of submaxillary gland in male Sprague Dawley rats [PDF]
, 2022 Xingfa Han +10 more
openalex +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source